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siveness to therapy and the number of disease relapses.
After multiple relapses, this lymphoma becomes refrac-
tory to standard therapies. Thus the median survival is
dramatically shortened to 24 to 26 months. Relapsed, re-
fractory low-grade lymphoma (RRLGNHL) is a common
disease progression and the focus of multiple studies in
the search for more effective therapies. Rituximab is an
anti-CD20 immunotherapy approved for the treatment
of RRLGNHL. It is marginally more effective in refrac-
tory cases than salvage therapy, but has a less severe side
effect profile. OBJECTIVE: To estimate the cost-effec-
tiveness ratio of rituximab in the treatment of RRLGNHL.
METHODS: The study utilized a societal perspective
with a two-year time horizon and an annual discount
rate of 3%. Outcomes data and their probabilities were
abstracted from randomized controlled trials for ritux-
imab and DHAP in RRLGNHL patient populations. Di-
rect medical costs, drug costs and health-state related
utilities were abstracted from other studies, standard
Medicare reimbursement rates and the Red Book. An in-
cremental cost-effectiveness ratio (ICE) was used to esti-
mate the effectiveness of rituximab compared to DHAP.
RESULTS: The study found an ICE ratio of $58,166 per
quality adjusted life-year saved. The model was found to
be sensitive to the medication costs, medication response
rates and the cost of autologous bone marrow transplan-
tation. CONCLUSION: Based on the findings, rituximab
appears to be a marginally cost-effective alternative for
RRLGNHL. Relative drug costs and response rates must
be considered before a conclusion can be drawn for a
specific institution.
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The aim of the trial was to compare using cost-effective-
ness analysis two schemes of chemotherapy in advanced
breast cancer as the first line of therapy. METHODS: Pa-
tients were randomly assigned to chemotherapy. Arm A:
standard scheme CAF (30 pts), and arm B: scheme TAD
(23 pts), 126 cycles. Effect was estimated after finishing 6
cycles. Results: CR or PR was seen in 78% of cases
(TAD) and 60% of cases (CAF). Stabilization of the pro-
cess was 13% and 23%, progression of the process was
9% and 17% accordingly. The cost of each cycle is as
follows: hospital expenditures, cost of diagnostic and
laboratory tests and expenses on medicine. The cost of 6
cycles per patient is 9845 USD (TAD) and 2140 USD
(CAF). But high level of effectiveness of this treatment
provides repayment that is demonstrated in table:
As a result of cost-effectiveness analysis the analysis of
clinical decisions was made and decision tree was built.
The final calculation of cost/ effectiveness index showed
advantages of TAD scheme compared to CAF scheme:
So, the advantage of the preliminary data of TAD scheme
according to rational utilization makes 37% compared to
CAF scheme.
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Epoetin alpha (EPO) usage increased five-fold during the
past three years at The University of Texas MD Ander-
son Cancer Center (UTMDACC). EPO has been shown
to be safe and might be considered more effective than
treatment with red blood cell infusions for patients with
chemotherapy-induced anemia. OBJECTIVE: To deter-
mine patterns of EPO usage in cancer patients and to
evaluate physicians’ adherence to proposed clinical guide-
lines. METHODS: We conducted a retrospective data-
base analysis for all in-patient EPO prescriptions processed
at the UTMDACC from March 1 to April 30 of 1999.
Patients receiving EPO during this period were each fol-
lowed throughout the course of their drug therapy. Data
was extracted for these patients using a pharmacy elec-
tronic database. The following information was coded:
administration dates, hemoglobin (Hgb) levels, units ad-
ministered, drug (EPO) cost, disease category, age, gen-
der, ethnic group, and residence. Based on the Hgb levels,
the data was coded into two groups, within or outside
proposed EPO guidelines and analyzed to evaluate pat-
terns of drug use. RESULTS: A total of 119 patients
(52% males) were identified with an average age of 57
years (range 9–81 years). Total drug cost per month for
all patients was $100,643. Around 35% (n  41) of pa-
Scheme
Average value
(USD)
Value of effective ChT (USD)
Remission Progression
TAD 9845 7705 13843
CAF 2140 1214 4207
It is according
4 cycles 7–8 cycles
Effect
Cost/effectiveness index
TAD CAF
General effectiveness 0,0006 0,0040
Remission
0,003
0,0137
